Your session is about to expire
← Back to Search
Dietary Supplement
Vitamin D + Omega-3 for Osteoporosis and Body Composition (VITAL Trial)
N/A
Waitlist Available
Led By Meryl S LeBoff, M.D.
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Those who are using bisphosphonates currently or within the past 2 years, or other bone-active medications currently or within the past year are not eligible for this study
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
VITAL Trial Summary
This trialis testing whether taking vitamin D and fish oil supplements prevents cancer, heart disease, and stroke in 25,871 U.S. men and women without prior illnesses. It also looks at the safety and efficacy of high-dose vitamin D on skeletal health and body composition.
Who is the study for?
The VITAL trial is for U.S. men and women who are part of the larger VITAL study, have no history of cancer, heart disease, or stroke, and aren't on bone-active medications currently or within the past year (or bisphosphonates within 2 years).Check my eligibility
What is being tested?
This trial tests if daily supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (1 gram fish oil) can reduce the risk of serious diseases like cancer and heart disease in healthy individuals.See study design
What are the potential side effects?
Potential side effects may include mild digestive discomfort from fish oil and possible high calcium levels or kidney stones from vitamin D3; however, these supplements are generally well-tolerated.
VITAL Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowVITAL Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Bone Turnover Beta Crosslaps
Bone Turnover P1NP
Change in Bone Density
Secondary outcome measures
Change in Bone Structure
Other outcome measures
Body Composition
VITAL Trial Design
4Treatment groups
Active Control
Placebo Group
Group I: Vitamin D + fish oilActive Control2 Interventions
Daily vitamin D (2,000 IU/d) and daily fish oil capsule (1 g/d; EPA + DHA in a 1.2:1 ratio)
Group II: Vitamin D placebo + fish oilActive Control2 Interventions
Daily vitamin D placebo and daily fish oil capsule (1 g/d; EPA + DHA in a 1.2:1 ratio)
Group III: Vitamin D + fish oil placeboActive Control2 Interventions
Daily vitamin D (2,000 IU/d) and daily fish oil placebo
Group IV: Vitamin D placebo + fish oil placeboPlacebo Group2 Interventions
Daily vitamin D placebo and daily fish oil placebo
Find a Location
Who is running the clinical trial?
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NIH
485 Previous Clinical Trials
1,086,138 Total Patients Enrolled
37 Trials studying Osteoporosis
40,420 Patients Enrolled for Osteoporosis
Brigham and Women's HospitalLead Sponsor
1,622 Previous Clinical Trials
11,467,986 Total Patients Enrolled
8 Trials studying Osteoporosis
63,894 Patients Enrolled for Osteoporosis
Meryl S LeBoff, M.D.Principal InvestigatorBrigham and Women's Hospital
2 Previous Clinical Trials
51,742 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I haven't used bisphosphonates or other bone medications in the required time frame.
Research Study Groups:
This trial has the following groups:- Group 1: Vitamin D + fish oil
- Group 2: Vitamin D placebo + fish oil
- Group 3: Vitamin D + fish oil placebo
- Group 4: Vitamin D placebo + fish oil placebo
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger